Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years : An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Walton, Matthew orcid.org/0000-0003-1932-3689, Sharif, Sahar, Simmonds, Mark orcid.org/0000-0002-1999-8515 et al. (2 more authors) (2019) Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years : An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. pp. 1209-1217. ISSN 1179-2027

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © Springer Nature Switzerland AG 2019. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details.
Keywords: Pharmacology,Health Policy,Public Health, Environmental and Occupational Health
Dates:
  • Accepted: 25 March 2019
  • Published: 13 April 2019
Institution: The University of York
Academic Units: The University of York > Faculty of Social Sciences (York) > Centre for Reviews and Dissemination (York)
Depositing User: Pure (York)
Date Deposited: 03 Apr 2019 12:50
Last Modified: 02 Jul 2020 15:50
Published Version: https://doi.org/10.1007/s40273-019-00799-0
Status: Published
Refereed: Yes
Identification Number: https://doi.org/10.1007/s40273-019-00799-0
Related URLs:

Download

Filename: Tisagenlecleucel_PE_accepted_manuscript.docx

Description: Tisagenlecleucel PE accepted manuscript

Share / Export

Statistics